Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Am J Hematol. 2017 Apr 18;92(6):E114–E117. doi: 10.1002/ajh.24720

Figure 1.

Figure 1

Survival of patients with relapsed/refractory Burkitt or high-grade B-cell leukemia or lymphoma. A) Overall survival measured from time of first treatment failure (N=35) and B) Relapse-free survival measured from time of second remission (N=11). C) Overall survival of patients with refractory disease or early relapse (initial remission duration <6 months) versus late relapse (initial remission duration ≥6 months). D) Overall survival of patients who responded to salvage chemotherapy versus those who did not respond.